Clinical Trials

1,207 enrolled 15 charts 2 FDA

Prostatic Neoplasms

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 2 FDA

Prostatic Neoplasms

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 3 FDA

Plasma cell

Smoldering Multiple Myeloma

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 2 FDA

Lymphoid

Hodgkin Disease

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 3 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04538664 2026-04-13

PAPILLON

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Plasma cell

Multiple Myeloma

NCT05388669 2026-04-13

PALOMA-3

418 enrolled 16 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04099251 2026-04-09

CheckMate76K

790 enrolled 18 charts 2 FDA

Dermatologic

Melanoma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 3 FDA

Plasma cell

Multiple Myeloma

NCT03395197 2026-04-07

TALAPRO-2

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04039607 2026-04-06

CheckMate 9DW

732 enrolled 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

405 enrolled 18 charts 3 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03701334 2026-04-01

NATALEE

5,101 enrolled 5 FDA

Breast

Breast Neoplasms

NCT02511106 2026-03-30

ADAURA

682 enrolled 20 charts 3 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

1,069 enrolled 19 charts 2 FDA

415 enrolled 3 FDA

Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Phase 3 Completed

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04656652 2026-03-24

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

605 enrolled 14 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04689828 2026-03-23

PSMAfore

469 enrolled 11 charts 3 FDA

Prostatic Neoplasms

NCT04924608 2026-03-23

KOMET

145 enrolled 17 charts 3 FDA

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03298451 2026-03-20

HIMALAYA

1,324 enrolled 31 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT05059262 2026-03-20

MOTION